Decreased serum fibroblast growth factor 19 level is a risk factor for type 1 diabetes.

ABSTRACT:

Background

Increasing evidence suggests that fibroblast growth factor 19 (FGF19) is a regulator of glucose metabolism and may provide a new therapeutic target for type 1 diabetes (T1D). However, the clinical relevance of FGF19 in T1D remains unclear. In this study, we examined the relationship between the serum FGF19 concentration and T1D.

Methods

This study included 81 newly diagnosed T1D patients and 80 sex- and age-matched healthy controls. The correlation between the FGF19 concentration and clinical characteristics of T1D patients and healthy controls was investigated. Logistic regression analysis was performed to determine whether levels of FGF19 were independently associated with T1D.

Results

The fasting serum FGF19 levels in the T1D group were significantly low

SUBMITTER: Hu J 

PROVIDER: S-EPMC8033349 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature